|
Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP) plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain—Primary safety results of the induction phase. |
|
Maria Rosario García Campelo |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; PharmaMar; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Merck; Roche |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche; Takeda |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche; Takeda |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche; Takeda |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche; Takeda |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Takeda |
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
Travel, Accommodations, Expenses - Lilly; Merck Sharp & Dohme; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Pfizer; Roche; Takeda |
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; Merck Sharp & Dohme; Pfizer; Roche; Takeda |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck Sharp & Dohme; Roche; Takeda |
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
|
|
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb |
Speakers' Bureau - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Roche; Sanofi |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Pfizer; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche |